- Home
- UWMC vs AVDL Comparison
UWMC vs AVDL Comparison
Compare UWMC & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- AVDL
- Stock Information
- Founded
- UWMC 1986
- AVDL 2015
- Country
- UWMC United States
- AVDL Ireland
- Employees
- UWMC N/A
- AVDL N/A
- Industry
- UWMC Finance: Consumer Services
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- AVDL Health Care
- Exchange
- UWMC Nasdaq
- AVDL Nasdaq
- Market Cap
- UWMC 1.4B
- AVDL 1.4B
- IPO Year
- UWMC N/A
- AVDL 1996
- Fundamental
- Price
- UWMC $6.87
- AVDL $15.44
- Analyst Decision
- UWMC Hold
- AVDL Strong Buy
- Analyst Count
- UWMC 7
- AVDL 8
- Target Price
- UWMC $5.54
- AVDL $20.88
- AVG Volume (30 Days)
- UWMC 8.9M
- AVDL 1.4M
- Earning Date
- UWMC 11-06-2025
- AVDL 11-11-2025
- Dividend Yield
- UWMC 5.79%
- AVDL N/A
- EPS Growth
- UWMC 112.84
- AVDL N/A
- EPS
- UWMC 0.07
- AVDL N/A
- Revenue
- UWMC $2,622,828,000.00
- AVDL $221,075,000.00
- Revenue This Year
- UWMC $25.96
- AVDL $63.77
- Revenue Next Year
- UWMC N/A
- AVDL $29.91
- P/E Ratio
- UWMC $104.25
- AVDL N/A
- Revenue Growth
- UWMC 13.45
- AVDL 132.35
- 52 Week Low
- UWMC $3.80
- AVDL $6.38
- 52 Week High
- UWMC $9.25
- AVDL $16.66
- Technical
- Relative Strength Index (RSI)
- UWMC 78.62
- AVDL 68.03
- Support Level
- UWMC $5.50
- AVDL $15.34
- Resistance Level
- UWMC $7.14
- AVDL $16.04
- Average True Range (ATR)
- UWMC 0.22
- AVDL 0.54
- MACD
- UWMC 0.09
- AVDL -0.05
- Stochastic Oscillator
- UWMC 88.25
- AVDL 77.05
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.